| 1. |
Masayuki Murata, Norihiro Furusyo, Jun Hayashi, Analysis for metabolic abnormalities associated with antiretroviral therapy in Japanese patients with human immunodeficiency virus-1 infection., The 85th European Atherosclerosis Society (EAS) congress 2017, 2017.04. |
| 2. |
Murata Masayuki, Recent trends in Influenza, 14th East Asian Conference on Infection Control and Prevention (EACIC) 2015, 2015.11. |
| 3. |
岡田 享子, 古庄 憲浩, 貝沼 茂三郎, 志水 元洋, 小川 栄一, 迎 はる, 豊田 一弘, 村田 昌之, 林 純, Raloxifene over 12 months improved the arterial stiffness and slowed the
carotid IMT progression of postmenopausal women, The 83rd European Atherosclerosis Society (EAS) Congress, 2015.03. |
| 4. |
志水 元洋, 古庄 憲浩, 光本 富士子, 高山 耕治, 浦 和也, 平峯 智, 池崎 裕昭, 居原 毅, 迎 はる, 小川 栄一, 豊田 一弘, 貝沼 茂三郎, 村田 昌之, 林 純, Subclinical carotid atherosclerosis predicts the incidence of chronic
kidney disease in a Japanese general population, The 83rd European Atherosclerosis Society (EAS) Congress, 2015.03. |
| 5. |
Murata Masayuki, Norihiro Furusyo, Eiichi Ogawa, Jun Hayashi, Beneficial effect of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response: 48 week result , 28th ICC (International Congress Chemotherapy and Infection )2013 , 2013.06. |
| 6. |
村田 昌之, 古庄憲浩, 小川栄一, 林 純, Beneficial effect of maraviroc, C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response , IDWeek2012, 2012.10. |
| 7. |
Surveillance for MRSA in Kyushu university hospital. |
| 8. |
Active surveillance culture for MRSA in Kyushu univesity hospital. |
| 9. |
Sharp injury prevention program for HBV, HCV and HIV. |
| 10. |
A case of catheter-related candida bacteremia successfully treated with liposommal amphotericin B. |
| 11. |
HBV and HIV coinfection. |
| 12. |
Infection control for influenza. |
| 13. |
Two cases of HCV and HIV coinfection with hemophilia treated by pegylated interferon and ribavirin. |
| 14. |
Analysis for metabolic abnormalities associated with antiretroviral therapy (ART) in Japanese patients with human immunodeficiency virus (HIV) infection
. |
| 15. |
A topic of infectious diseases. |
| 16. |
YMDD mutation and deterioration of liver function in Japanese chronic hepatitis B patients undergoing long-term lamivudine treatment. |
| 17. |
Sharp injury prevention program for HBV, HCV and HIV in Kyushu university hospital. |
| 18. |
Analysis for clinical features in patients with HBV and HIV coinfection in Fukuoka, Japan. |
| 19. |
Analysis for clinical features in patients with HBV and HIV coinfection in Fukuoka, Japan. |
| 20. |
Infection control in Fukuoka city. |
| 21. |
Analysis for HBV/HIV coinfection in Fukuoka city. |
| 22. |
Post exposure prophylaxis for HBV, HCV and HIV. |
| 23. |
Post exposure prophylaxis for HBV, HCV and HIV. |
| 24. |
Post exposure prophylaxis for HIV. |
| 25. |
Analysis for 35 Japanese patients with HIV/AIDS . |
| 26. |
Influenza 2010/2011. |
| 27. |
Analysis for HBV/HIV coinfection in Fukuoka city. |
| 28. |
Infection control for drug resistant bacterium. |
| 29. |
Pandemic influenza H1N1 2009. |
| 30. |
A Japanese case of AIDS-associated Kaposi sarcoma. |
| 31. |
Analysis for metabolic abnormalites associated with highly active antiretroviral therapy (HAART) in Japanese patients with human immunodeficiency virus (HIV) infection. |
| 32. |
Clinical feature in patients with acute HIV infection. |
| 33. |
Analysis of YMDD mutation during long-term lamivudine therapy for Japanese patients with chronic hepatitis B using real-time PCR with the LightCycler assay. |
| 34. |
management of antibiotics usage for resident doctors. |
| 35. |
management of pandemic Flu (H1N1). |
| 36. |
management of HIV/AIDS. |
| 37. |
Analysis for metabolic abnormalities associated with the highly active antiretroviral therapy (HAART) in Japanese patients with human immunodeficiency virus (HIV). |
| 38. |
Analysis for metabolic abnormalities associated with the highly active antiretroviral therapy (HAART) in Japanese patients with human immunodeficiency virus (HIV). |
| 39. |
The analysis for linezolid therapy in Kyushu-University Hospital. |
| 40. |
The analysis for MRSA genotyping by detecting phage-derived open-reading frames in Kyushu-University Hospital. |
| 41. |
management of pandemic Flu (H1N1) in Kyushu-University Hospital. |
| 42. |
management of pandemic Flu (H1N1) in Kyushu-University Hospital. |
| 43. |
management of pandemic Flu (H1N1) in Kyushu-University. |
| 44. |
Management of occupational exposures to HIV and recommendations for postexposure prophylaxis. |
| 45. |
The aim of this study was to determine the efficacy of PegIFN-alpha plus RBV treatment for Japanese patients infected with HCV. In total, 201 patients with genotype 1 and HCV RNA level 100 kIU/mL or over received PegIFN-alpha subcutaneously once a weekly and daily RBV for 48 weeks. The overall sustained virological response (SVR) (undetectable serum HCV RNA) 24 weeks after end of treatment was 41.8% by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without discontinuation of the 48-week treatment (48.4% vs. 20.8%), but no difference was found between those with and without a dose reduction of these drugs. Multiple regression analysis showed younger age, lower gamma-glutamyltransferase, higher platelet count at baseline to be significantly independent parameters associated with SVR. The low gamma-glutamyltransferase is an independent predictive SVR factor newly added to the usual ones in PegIFN-alpha plus RBV treatment for Japanese chronically HCV-infected patients.. |
| 46. |
Evaluation of a new tabletop washer-disinfector, WD-32, for the virological disinfection of medical device.. |
| 47. |
The analyses for cytokine-producing peripheral CD8+ T cells and activation marker of peripheral CD8+ T cells in chronic hepatitis C patients during IFN theray.. |
| 48. |
Evaluation of a new ozone apparatus, the BOX-O3, for the bacteriological disinfection of medical waste.. |
| 49. |
The comparison of antitumor effects on HCC cell lines between IFN-beta and alpha. |
| 50. |
The analyses for IFN-gamma-producing peripheral CD8+ T cells in patients with chronic hepatitis C. |
